Search results
Jemperli contends with blockbuster Keytruda in endometrial cancer
Clinical Trials Arena via Yahoo Finance· 6 days agoJemperli is a monoclonal antibody targeting PD-1, an inhibitory immunological checkpoint receptor,...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The Sun Chronicle· 4 days agoWALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2024 the
BioNTech reports net loss of €315.1m in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 13 hours agoWe look forward to providing more updates this year across our oncology portfolio, including our bispecific antibody and ADC programmes. “In the...
Managing Thyroid Adverse Events From Checkpoint Inhibitors
Medscape· 19 hours agoFor today's episode, we are focusing on a very specific, yet increasingly relevant topic: the...
Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 14 hours ago(NASDAQ:FGEN) has reported its financial results for the first quarter of 2024, emphasizing its...
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 2 hours agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published ...
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
WJTV Jackson· 12 hours agoElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range ...
New approach for developing cancer vaccines could make immunotherapies more effective in acute...
Medical Xpress· 4 days agoIn a new study published in Blood Advances, researchers from the UChicago Pritzker School of...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
WTNH-TV New Haven· 2 days agoCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a...
Pfizer cervical cancer drug gets full approval
Becker’s Hospital Review· 5 days agoThe FDA has granted full approval for Pfizer's Tivdak (tisotumab vedotin-tftv) to treat cervical cancer in patients whose disease has progressed on or after chemotherapy.
